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Abstract
Chagas disease, caused by the protozoan Trypanosoma cruzi, is endemic to 
Latin America, standing out as a socio-economic problem for low-income tropi-
cal populations. Such disease affects millions of people worldwide and emerges in 
nonendemic areas due to migration and climate changes. The current chemotherapy 
is restricted to two nitroderivatives (benznidazole and nifurtimox), which is unsat-
isfactory due to limited efficacy (particularly in chronic phase) and adverse side 
effects. T. cruzi life cycle is complex, including invertebrate and vertebrate hosts 
and three developmental forms (epimastigotes, trypomastigotes, and amastigotes). 
In this chapter, we will discuss promising cellular and molecular targets present in 
the vertebrate-dwelling forms of the parasite (trypomastigotes and amastigotes). 
Among the cellular targets, the mitochondrion is the most frequently studied; while 
among the molecular ones, we highlight squalene synthase, C14α-sterol demeth-
ylase, and cysteine proteases. In this scenario, proteomics becomes a valuable tool 
for the identification of other molecular targets, and some previously identified 
candidates will be also discussed. Multidisciplinary studies are needed to identify 
novel key molecules in T. cruzi in order to increase trypanocidal activity and reduce 
mammalian toxicity, ensuring the development of novel drugs for Chagas disease.
Keywords: Trypanosoma cruzi, Chagas disease, chemotherapy, drug targets, 
organelles, proteomics, oxidative metabolism
1. Introduction
Chagas disease, or American trypanosomiasis, was described in 1909 by the 
Brazilian physician Carlos Chagas, who identified the causative agent—Trypanosoma 
cruzi—the transmission vector, major reservoirs, mechanism of human infection, 
as well as some clinical manifestations [1]. This disease is primarily transmitted to 
humans by the feces of hematophagous insects, of the family Reduviidae, subfamily 
Triatominae. The impressive decrease in Chagas disease prevalence from 16–18 mil-
lion people by 1990 to 6–8 million people by 2010 was essentially the consequence 
of the launching of transnational programs in Latin America focused on the elimi-
nation of domestic vectors and blood donors screening supported by Pan American 
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Health Organization/World Health Organization (PAHO/WHO) [2]. Despite these 
successful control interventions, the Chagas disease prevalence was estimated to 
reach 1.0–2.4% of the Brazilian population [1]. This disease, classically associated 
with poor and rural populations, underwent an urbanization process in the 1970s 
and 1980s to Latin American cities and later on beyond endemic countries, creating 
new epidemiological, social, and political challenges [3–5].
With the success of vector and blood bank control programs, congenital [6, 7], 
and oral [8, 9] transmissions have become important sources of new cases of Chagas 
disease. Congenital infections represent an estimated 22% of new cases in Latin 
America [2], occurring also in nonendemic countries [10, 11]. The oral route, which 
is probably the most frequent mechanism among vectors and wild mammals, has 
recently become relevant, due to environmental changes caused by deforestation 
[12]. T. cruzi DNA was recently shown in 10% among 140 samples of açai-based 
products marketed in Rio de Janeiro and Pará States in Brazil [13].
Chagas disease results from the establishment of T. cruzi in host tissues, involv-
ing an initial acute phase followed by a chronic phase, classified as indeterminate, 
cardiac, and/or digestive syndromes. The acute phase is characterized by detectable 
parasitemia and is commonly asymptomatic [14]. Without treatment, approxi-
mately 5–10% of symptomatic patients die during this phase due to encephalomyeli-
tis or severe cardiac failure and rarely due to cardiac arrest [15]. After 2–3 months, 
the infection enters the chronic phase, and without successful treatment, it is 
lifelong. Approximately, two-thirds of infected individuals have the indeterminate 
form of the chronic phase, which is asymptomatic and defined by the presence 
of T. cruzi antibodies and normal electrocardiographic and radiologic exams. The 
remaining infected individuals, due to an unbalanced inflammatory response and 
persistent low parasitism, will develop years or even decades later symptomatic 
chronic disease with cardiac (20–30%) and/or digestive (15–20%) disorders.
The current etiological treatment for Chagas disease is restricted to two nitro-
heterocyclic drugs: benznidazole (Bz/LAFEPE, Abarax®, ELEA and Bz/Chemo 
Research, Exeltis) and nifurtimox (Nif, LAMPIT®, Bayer) (Figure 1). Bz has been 
recently FDA-approved for use in children aged 2–12 years, being the first treat-
ment approved in the United States for Chagas disease [16]. The results obtained 
with these two nitroderivatives vary according to the phase of Chagas disease, the 
period, and dose of treatment, as well as the age and geographical origin of the 
patients [17]. Both drugs have often shown successful results with high parasitologi-
cal cure rates during the acute phase, but the effectiveness decreases with advance 
of the infection; therefore, early detection and intervention are crucial for reaching 
high cure rates [18]. The high incidence of collateral effects, especially for adults, 
leads to treatment abandonment rates reaching over 30% of the patients [19–21]. In 
contrast, children have a markedly higher tolerance for treatment [1, 14].
There are significant drawbacks on the use of these drugs, mostly related to 
the limited efficacy in the chronic phase [22], and so, new alternative therapies 
Figure 1. 
Clinical drugs for Chagas disease treatment: (A) benznidazole and (B) nifurtimox.
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are urgently required. In the last decades, many chemical diversity libraries from 
several pharmaceutical companies have been screened in the search of novel anti-T. 
cruzi candidates. In these programs, different approaches have been used including 
target-oriented studies, combination therapies, new formulations for drugs in use, 
and drug repurposing, and thus, in the present review, some of these points will be 
addressed.
2. Trypanosoma cruzi and drug targets
One important point to be addressed in the search of alternative molecular 
targets in T. cruzi is their presence in parasite forms dwelling in vertebrates. Once 
the parasite stages present different metabolic profiles [23, 24], the most promising 
targets are involved in crucial metabolic pathways, such as key enzymes related to 
antioxidant metabolism or sterol biosynthesis. In this section, we revised some of 
the most studied targets for drug intervention.
2.1 Mitochondrion, glycosomes, and oxidative metabolism
Mitochondrion plays a pivotal role in the oxidative stress, since the electron 
leakage from the electron transport chain (ETC particularly from complexes I, III 
and coenzyme Q ) leads to the partial reduction of oxygen, being the main source of 
reactive oxygen species (ROS) in the cells [25]. During electron leakage, ROS were 
produced that interfere with different biological processes [26]. Such production 
leads to the increase in the expression of antioxidant enzymes such as superoxide 
dismutase (SOD), trypanothione reductase (TR), and peroxidases in response to the 
oxidative burst, and TR is considered one of the most promising chemotherapy tar-
gets in Chagas disease [27]. In trypanosomatids, mitochondrial metabolism is quite 
similar to that of other eukaryotes. Complex I (NADH: ubiquinone oxidoreductase) 
is expressed (almost 19 subunits were detected) but its functionality is still contro-
versial [26]. In this way, glucose metabolism results mostly in succinate (complex II 
substrate) in trypanosomatids, derived from glycosomal and mitochondrial NADH-
dependent fumarate reductase activities [28, 29]. Since complex I is not functional, 
oxidative phosphorylation is exclusively dependent of complex II in these protozoa. 
On the other hand, complexes III (ubiquinol:cytochrome c oxidoreductase) and IV 
(cytochrome c oxidase) of high eukaryotes and trypanosomatids display no differ-
ences, being complex III considered the major mitochondrial source of ROS pro-
duction [30]. Many studies pointed to the susceptibility of T. cruzi mitochondrion 
to a great variety of compounds, and such mitochondrial damage (ultrastructural 
swelling, decreased mitochondrial membrane potential, etc.) may comprise early or 
late events in trypanocidal agent activity (Figure 2) [31].
Glycosomes are organelles crucial for the energetic and antioxidant metabolisms 
of the parasite, and the compartmentalization of their enzymes (including the 
majority of the enzymes of the glycolytic pathway) has also been reported to be 
directly involved in the maintenance of T. cruzi viability, indicating this organelle as 
a potential drug target [32]. Among the glycosomal oxidative, scavengers are SOD 
isoforms, tryparedoxin, and peroxidases [26]. Up to now, no specific inhibitors of 
glycosomal enzymes showed promising trypanocidal activity [33].
2.1.1 Mitochondrial ETC
T. cruzi mitochondrion is the most recurrent cellular drug target described 
in mechanistic studies; however, the exact molecular machinery involved in the 
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susceptibility of this organelle to different classes of compounds is still unclear 
[31]. No hypothesis about the molecular mechanism involved in the mitochon-
drial effect of the great majority of trypanocidal drugs was postulated hitherto, 
and the damage specificity in this organelle is very debatable. Some specific 
inhibitors of ETC complexes have already been tested on T. cruzi. Rotenone, 
a well-known complex I inhibitor, has a controversial activity in the parasite. 
However, rotenone at high doses inhibited the activity of T. cruzi NADH-
dependent enzymes [34]. The existence of complex I activity was not strongly 
supported by such inhibition and could be caused by nonspecific binding to other 
electron carriers. On the other hand, depolarization of mitochondrial membrane, 
ROS production, and apoptotic-like phenotype was detected in parasites after the 
treatment with inhibitors of complexes III and IV, antimycin A, and potassium 
cyanide, respectively [24]. Structural and functional similarities between mam-
malian and trypanosomatidae complexes are suggestive of high toxicity.
2.1.2 Trypanothione reductase
The presence of some antioxidant components that are absent in mammalian 
cells makes this pathway a promising target of drug intervention in trypanosoma-
tids. The unusual spermidine-glutathione adduct named trypanothione or N1,N8-
bis(glutathionyl)spermidine found solely in these parasites functions as an electron 
donor in many pathways by neutralizing diverse reactive species through redox 
reactions, also providing reducing equivalents to intermediate molecules in other 
antioxidant pathways and in biosynthetic pathways such as DNA synthesis [35, 36]. 
The catalysis of NADPH-dependent reduction of trypanothione disulfide to T(SH)2 
is performed by trypanothione reductase (TR), enzyme that has been proposed as 
a molecular target, based on the specific inhibition of antioxidant defenses of the 
parasite [37, 38]. The central role of trypanothione makes other enzymes that influ-
ence its production also interesting drug targets such as trypanothione synthetase, 
ornithine decarboxylase (ODC), S-adenosylmethionine (AdoMet) decarboxylase, 
γ-glutamylcysteine synthetase as well as polyamine transporters [39, 40].
In the last decades, many TR inhibitors were developed, but only a few had a 
positive correlation between trypanocidal activity and binding to the enzyme dem-
onstrated [41–43]. Recently, a high-throughput screening of 1.8 million compounds 
Figure 2. 
Most recurrent cellular drug targets in T. cruzi mammalian stages. M: mitochondrion; K: kinetoplast; N: nucleus; 
F: flagellum; Gl: glycosomes; G: golgi; Ac: acidocalcisomes; ER: endoplasmic reticulum; and Ap: autophagosomes.
5Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease
DOI: http://dx.doi.org/10.5772/intechopen.84472
was performed, and specific inhibitors of Leishmania TR were identified. Since this 
enzyme is considered well-conserved among trypanosomatids, this study could 
represent a critical step for the identification of inhibitors also for T. cruzi TR [44]. 
Up to the moment, the inhibition of trypanothione metabolism of this parasite was 
poorly assessed in animal models, and no clinical trial has been reported involving 
this target (Figure 3).
2.1.3 ROS inducers
Varying the dose or the time of drug treatment, injury to the mitochondrion 
usually leads to ROS production [45]. Despite many compounds having induced 
mitochondrial alterations, generating ROS, the molecular mechanistic action 
was not elucidated in most studies. In this section, we will discuss only qui-
nones and nitrocompounds, compounds with oxidative mechanisms of action 
well-characterized.
Quinones: Chemical properties of quinoidal carbonyls lead to the direct ROS 
generation [46], and trypanocidal effect of natural quinones and derivatives have 
been assessed [47–50]. In epimastigotes, the oxidative activity of β-lapachone was 
first reported almost 40 years ago [51, 52], and increase in ROS levels has also been 
related to the treatment of T. cruzi with other naphthoquinones [53, 54]. In 2009, 
we proposed the trypanocidal mechanism of action of naphthofuranquinones. 
Such quinones strongly impaired the parasite mitochondrion by the deviation 
of the electrons from ubiquinone, culminating in this organelle  depolarization, 
loss of respiratory rates, inhibition of complexes I–III activities, and ROS 
 production [54]. Increased levels of ROS were also detected in parasites after the 
 treatment with other classes of compounds such as pyrazyl/pyridylhydrazones and 
 thiosemicarbazones [55–57].
Nitrocompounds: These compounds are usually avoided in medicinal chemistry 
approaches because the presence of a nitro group creates concerns regarding toxic-
ity issues associated with DNA damage [58]. Regarding Chagas disease, fexinidazole 
evaluated in vivo, led to high cure rates and reduced myocarditis [59]. Subsequently, 
a phase II clinical trial was performed in chronic chagasic patients in Bolivia using 
fexinidazole treatment (NCT02498782), and it was observed that parasitemia was 
cleared; however, after recruiting 47 participants, some safety and tolerability 
issues arose, and it was decided to conclude the trial without the inclusion of new 
participants. After a 12 month follow-up, a high efficacy rate was evidenced, with-
out relapses [60]. Therefore, a new proof of concept study was initiated in Spain in 
2017, with the results expected in 2019 (EudraCT Number 2016-004905-15).
Figure 3. 
Landmarks in the investigation of TR as a drug target. Despite many efforts up to now, specific inhibitors of 
this enzyme presented neither important trypanocidal activity in vitro nor in vivo. TR DPB ID: 1BZL.
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Surprisingly, trypanocidal action of Nif and Bz is still controversial. Nif has the 
oxidative activity demonstrated in the early 1980s, being hydrogen peroxide and 
superoxide anion production detected, while no reactive species was found after the 
treatment with Bz [61]. Bz and Nif are considered prodrugs that require activation 
by nitroreductases—NTR-I, an oxygen insensitive class catalyzing the two-electron 
reduction of the nitro group and NTR-II, an oxygen-sensitive class catalyzing 
one-electron reduction [62]. The mechanistic proposal of Nif involves nitroanion 
radical metabolization by NTR-II, followed by reoxidation by molecular oxygen 
to form superoxide anion (∙O2
−), which is converted to hydrogen peroxide (H2O2) 
under catalysis by SOD (Figure 4) [63]. On the other hand, low molecular weight 
thiol reduction together with no redox cycling in trypanocidal doses supported the 
hypothesis that oxidative effect was not involved in the parasite killing by Nif [64]. 
Additionally, NTR-I activity has been related to the trypanocidal effect of Nif and 
Bz through a two-electron reduction in the nitro group. In an oxygen-independent 
way, the production of nitroso and hydroxylamine intermediates led to amine 
generation, using NADH as a cofactor. The cleavage of the Nif furane ring produces 
a highly reactive unsaturated open chain nitrile [65].
Recently, some highly potent 3-nitro-1H-1,2,4-triazole derivatives emerged 
as excellent substrates for NTR-I, but the enzymatic activity was not required for 
the trypanocidal activity [66]. Alternative enzymes have been associated with the 
reduction of nitro compounds in T. cruzi, indicative of a secondary action for these 
drugs, and further studies about the molecular mechanisms involved must be per-
formed. The high trypanocidal activity together with the identification of exclusive 
nitroreductases in trypanosomatids supports the hypothesis of selectivity [63].
2.1.4 Polyamines
Polyamines (PA) are ubiquitous organic polycations that play a plethora of 
ubiquitous biological roles in most cell types, including bacteria, protozoa, and 
higher organisms [67], with significant metabolic differences, therefore compris-
ing promising drug targets for protozoal diseases [68]. PA metabolism among 
parasitic protozoa is defective in a number of pathways as compared to mammalian 
cells. T. cruzi parasites lack ODC and so are auxotrophic for the diamine putrescine 
[69]. Therefore, the protozoan relies on the diamine uptake from the extracel-
lular milieu via surface transporters or permeases [70], and so, these mechanisms 
comprise targets for chemotherapy agent development [71], and pentamidine was 
shown to inhibit polyamine transport by T. cruzi [72]. Putrescine uptake is required 
for the massive infection [73] and scape from stress conditions [74]. Spermidine 
is synthesized by the transfer of an aminopropyl group from decarboxylated 
S-adenosyl-l-methionine to putrescine and takes part in the biogenesis of T[SH]2 
a pivotal adduct in oxidative stress endurance and involved in anti-T. cruzi drug 
Figure 4. 
Metobolization of nitrocompounds by NTR-1 and NTR-II. ROS is generated by reoxidation (one electron 
route). Two-electron reduction produces hydroxylamine intermediates and reactive nitroso [63].
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resistance [75]. In this regard, the putrescine analog DAB (1,4-diamino-2-buta-
none) promotes oxidative stress in T. cruzi [76] and leads to T. cruzi mitochondrial 
destruction [77]. It is noteworthy that DAB not only is involved on reactive species 
production but also inhibit putrescine synthesis [78] and incorporation [79].
Polyamines may play multiple functions in parasite endurance under oxidative 
stress conditions, not only for TSH is a spermidine adduct but also because these 
polycations per se may be antioxidant, protecting T. cruzi from oxidative stress [80]. 
Polyamines are also relevant for controlling differentiation, including T. cruzi meta-
cyclogenesis [81]. Thus, the enzymes involved in polyamine and TSH metabolism 
provide important drug targets for potential anti-T. cruzi therapy [40].
2.2 Biosynthesis of sterols
Sterols are essential lipid molecules, performing numerous cellular roles associ-
ated with membrane and signal functions [82]. Cholesterol is biosynthesized in 
humans, whereas ergosterol or other 24-alkylated sterols are biosynthesized in 
opportunistic fungi and parasitic protozoa and such difference is exploited in the 
drug development [83]. T. cruzi and related trypanosomatids have a strict require-
ment for endogenous sterols (ergosterol and analogs) for survival that cannot be 
replaced by cholesterol found in the host. Thus, the biosynthesis of sterols is a major 
target in the drug development for Chagas disease [84]. Among enzymes of the 
sterol metabolism, squalene synthase (SQS) and C14α-sterol demethylase (CYP51) 
have been intensively investigated as drug targets (Figure 5).
2.2.1 Squalene synthase (SQS)
This enzyme catalyzes the dimerization of two molecules of farnesyl pyrophos-
phate (FPP) to produce squalene. This enzyme is under study as a possible target 
for cholesterol-lowering agents in humans [85]. SQS is a membrane-bound enzyme 
Figure 5. 
Ergosterol biosynthesis is an important drug target in T. cruzi. In red, the enzymes described as molecular 
targets and in blue, the classes of the speciffic inhibitors. Inside gray boxes, the intermediary steps of the 
conversion of lanosterol into 4,4-dimethyl-5a-cholesta-8,1,4,24-3b-ol by sterol 14-α-demethylase (CYP51).
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in T. cruzi epimastigotes, being distributed between glycosome and mitochondrial/
microsomal vesicles [86]. FPP is a branching point in isoprenoid biosynthesis: 
conversion to squalene and sterols by SQS or synthesis of other essential isopren-
oids. The quinuclidine-based inhibitors of mammalian SQS, 3-(biphenyl-4-yl)-
3-hydroxyquinuclidine (BPQ-OH) ER27856, E5700, and ER-119884 were assayed 
against T. cruzi, leading to the in vitro inhibition of epimastigote and intracellular 
amastigote proliferation, depletion of endogenous squalene and sterols, and marked 
ultrastructural alterations [86, 87] and in vivo E5700 led to 100% survival and 
parasitemia negativation [88]. However, E5700 and ER-119884 have no selectivity 
toward the parasite enzyme in comparative assays with the recombinant human 
enzyme [89]. In 2014, the X-ray crystallographic structure of SQS from T. cruzi was 
reported, confirming the binding of the enzyme to distinct classes of inhibitors 
such as the quinuclidines E5700 and ER119884 and the thiocyanate WC-9 opening 
possibilities to the development of alternative inhibitors [90].
In a screening of compounds containing the 4-phenoxyphenoxy skeleton, 
4-phenoxyphenoxyethyl thiocyanate (WC-9) was highlighted due to the high activ-
ity against the proliferative form epimastigotes (low micromolar) and intracellular 
amastigotes (nanomolar) and a potent inhibitor of the enzymatic activity of both 
glycosomal and mitochondrial isoforms of SQS [91, 92]. Since then, different series 
of WC-9 analogs have been developed [91, 93], including seleno-containing analogs 
resulting in compounds, such as 4-phenoxyphenoxyethyl selenocyanate, with EC50 
values at low nanomolar level and selectivity index (SI) higher than 900 [94].
2.2.2 C14α-sterol demethylase (CYP51)
This enzyme catalyzes the oxidative removal of the 14α-methyl group from of 
catalyzing the oxidative removal of the 14α-methyl group from sterol precursors 
such as lanosterol or eburicol, via a repetitive three-step process that uses NADPH 
and oxygen to produce 4,4-dimethyl-5α-cholesta-8,14,24-trien-3β-ol [83]. CYP51s 
are the most conserved cytochrome P450 enzymes [84]. Series of azoles originally 
developed for the treatment of fungal infections targets this enzyme leading to accu-
mulation of lanosterol and other sterol intermediates and displaying activity in vitro 
and in vivo against T. cruzi [95–97]. This line of investigation led to the selection of 
the triazole posaconazole [98, 99] and E1224 (fosravuconazole) [100, 101] for Phase 
II clinical trials with chronic patients, which, however, led to therapeutic failure as 
compared to benznidazole, with parasitemia relapses: NCT01162967 (Chagazol) 
[102], NCT01377480 (Stopchagas) [103], and NCT01489228 (E1224 trial) [104].
VNI, a carboxamide-containing β-phenyl-imidazole, identified from a Novartis 
collection of azoles, was active in acute and chronic mouse models using Tulahuen 
strain [105]; whereas in experiments with other parasite strains, no complete para-
sitological clearance was achieved [106]. In subsequent work, VFV, a fluoro analog 
of VNI, designed to fill the deepest portion of the CYP51 substrate-binding cavity 
demonstrated 100% efficacy in experimental infection, displaying favorable oral 
bioavailability and pharmacokinetics [107]. Comparison between VNI and VFV, 
in murine models of infection, revealed that regardless of the treatment scheme or 
delivery vehicle, VFV was more potent in both genders [108]. VT-1161, a 1-tetra-
zole-based drug undergoing phase II antifungal clinical trials, is active in vitro and 
in vivo against T. cruzi. It was structurally characterized in a complex with TcCYP51, 
allowing for the optimization of new tetrazole-based analogs and presents good 
pharmacokinetic properties and an excellent safety profile [109]. Friggeri et al. 
[110] synthesized imidazolyl-2-phenylethanol derivatives, and several of them were 
active against intracellular amastigotes and inhibited TcCYP51. In sequence, eight 
new derivatives were prepared and assayed against the parasite, and the most active 
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was a piperazinyl-carbamate derivative at nanomolar range, low cytotoxicity, and 
good chemical and metabolic stability [111]. Recently, a series of pyrazolo[3,4-e]
[1,4]thiazepin analogs, novel CYP51 inhibitors, were investigated revealing in vitro 
and in vivo activity against T. cruzi, with several analogs displaying effect at low 
micromolar dosis and low host toxicity [112].
2.3 Cysteine proteases
Cysteine proteases are intensively used as molecular targets in trypanosomatid 
disease drug discovery efforts. Target-based screening, structure-based drug 
design, and medicinal chemistry approaches targeting cysteine proteases are strate-
gies intensively used in the development of drugs for diseases caused by pathogenic 
trypanosomatids. T. cruzi cysteine protease named cruzipain (or cruzain) is a 
cathepsin-L-like protease of the papain family and is essential for the intracellular 
replication, differentiation, and immune evasion of the parasite [113, 114]. Three-
dimensional structures of cruzain with different ligands have been reported, allow-
ing the design and synthesis of new hit compounds [115]. Based on the interaction 
with its active site, enzyme inhibitors have been classified as irreversible, forming 
covalent bonds with cysteine sulfur, or as reversible, forming 1,2-adducts with 
cysteine that are generally unstable [116]. Among irreversible peptidyl inhibitors 
of cruzipain, we highlight diazomethyl ketones, allyl sulfones, vinyl sulfonamides, 
and vinyl sulfones, including K777 and its arginine variant WRR-483 [117–119]. 
Among nonpeptidyl inhibitors of cruzipain, we found thiosemicarbazones, thiazo-
lylhydrazones, thiazoles, and oxadiazoles (Figure 6) [120].
Another group of compounds that has been studied as cruzipain reversible 
inhibitors are those containing a nitrile head: purine nitriles [121], nitrile analogs 
of odanacatib [122, 123], and nonpeptidic nitriles [124]. Salas-Sarduy et al. [125] 
identified two new cruzipain inhibitory scaffolds from GlaxoSmithKline HAT and 
Chagas chemical boxes, both containing a nitrile moiety, with major structural dif-
ferences between them. Benzimidazoles and oxidiazoles have also been explored as 
noncovalent cruzain inhibitors, using an approach combining high throughput and 
virtual screenings [126, 127].
Development of cruzipain inhibitors by structure activity relationship (SAR) 
studies, combinatorial chemistry, HTS, and virtual screening are also employed 
in repositioning strategies [128]. Bromocriptine (antiparkinson and antidiabetic 
Figure 6. 
Cruzipain as a molecular target in T. cruzi. Irreversible and reversible inhibition was demonstrated by 
different classes of compounds. Cruzipain PDB ID: 3Io6.
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drug), amiodarone (antiarrhythmic drug), and levothyroxine (hypothyroidism 
drug) were selected in a screening campaign for cruzain inhibitors of the DrugBank 
database [129], clofazimine (antileprosy drug) and benidipine (antihypertensive) 
from the Merck Index 12th database [130, 131], and etofyllin clofibrate (antilipemic 
drug) and piperacillin, cefoperazone, and flucloxacillin (β-lactam antibiotics) from 
a collection of 3180 FDA drugs [132].
Calpains are calcium-dependent nonlysosomal cysteine peptidases highly 
conserved among eukaryotes, but their precise biological function is not completely 
clear. In mammalian cells, calpains participate in many different calcium processes 
including proliferation, differentiation, cytoskeletal assembly, cellular signaling, 
among many others; however, T. cruzi calpains do not present a mapped active 
catalytic site up to now [133]. In man, uncontrolled activity of calpains has been 
associated with muscular and neurological disorders such as Alzheimer, Parkinson, 
multiple sclerosis, and arthritis, and the terapeutic effect of specific calpain inhibi-
tors was suggested [134, 135]. Recently, the repurposing of calpain inhibitors was 
also postulated for neglected tropical diseases, including Chagas disease [133]. In 
T. cruzi, only the inhibitor MDL28170 was tested, and the trypanocidal activity at low 
micromolar range was shown on all three parasite forms, impairing the ultrastruc-
tural architecture of Golgi and reservosomes [136, 137]. Despite the study’s scarcity, 
calpains inhibition has been suggested as an attractive antitrypanosomatid approach 
even without the confirmation of their proteolytic activity in these parasites.
2.4 Nuclear and kinetoplast DNA
Both T. cruzi kinetoplast and nucleus may be targeted by different classes of 
compounds with antiparasitic activity [138, 139]. Early studies [140] revealed 
that hydroxystilbamidine led to the disorganization of kinetoplast DNA (kDNA). 
Later other compounds such as vinblastine, geranylgeraniol, diaminobenzidine, 
and aromatic diamidines were reported to affect kDNA arrangement causing its 
fragmentation [138, 141, 142]. Trypanosomatid nucleus and kinetoplast display 
topoisomerases that show significant structural differences from host orthologs 
advocating their potential as drug targets [143]. Interestingly, T. cruzi topoisomer-
ase I is inactivated by ROS [144], so the oxidative stress induced by both immune 
response and trypanocidal agents may also affect parasite chromatin organization.
Classic aromatic diamidines have been shown to bind noncovalently and 
through a nonintercalative manner to the minor groove of DNA; several hypotheses 
regarding their mode of action were proposed. They could act by complexation with 
DNA and subsequently lead to a selective inhibition of DNA-dependent enzymes 
and/or through the direct inhibition of transcription [145]. Thus, evidences suggest 
that diamidines interfere in the kinetoplast function of trypanosomatids through 
a selective association to the unique AT-rich regions of kDNA minicircles, perhaps 
involving DNA-processing enzymes [146]. Medicinal chemistry studies pointed 
to arylimidamides (AIAs) as the most promising antimicrobial diamidines [106]. 
DB702, DB786, DB811, and DB889 presented anti-T. cruzi activity in the low-
micromolar range and led to ultrastructural alterations mainly associated with the 
nucleus and mitochondrion [147, 148]. On the other hand, recent study with novel 
bis-AIAs revealed their higher potency and in silico analysis showed DNA as the 
main target, but no DNA ultrastructural alterations were found [149].
On the other hand, enzymes involved in nucleic acid metabolism could be also 
promising targets. Topoisomerases play a crucial role for the DNA dynamics during 
the transcription, replication, or even in the repair. Due to their participation in 
essential cellular processes, interfering with DNA topology, and consequently lead-
ing to physiological implications, topoisomerases have been described as molecular 
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targets for cancer and also parasitic illnesses such as Chagas disease. Up to now, 
innumerous topoisomerase inhibitors presented antitrypanosomatidae activi-
ties such as camptothecin, doxorubicin, etoposide, suramin, among many others 
[150]. Recently, voacamine and an isobenzofuranone derivative induced important 
morphological alterations in different trypanosomatids, including T. cruzi. In 
Leishmania parasites, the most affected organelle was mitochondrion (severely 
swelled presenting membrane depolarization), where the derivative led to kineto-
plast network disorganization [151, 152].
3. Proteomic insights for the target identification in the parasite
The evaluation of the proteomic profile in trypanosomatids is particularly inter-
esting because these protozoa exhibit open reading frames in long polycistronic 
regions, and the regulation of gene expression occurs only post-transcriptionally, 
justifying the importance on monitoring the protein expression by proteomic 
approach [153]. This section will focus on proteomic analysis of parasite forms 
dwelling in mammalian hosts. The first large-scale analysis was performed by 
Atwood and colleagues in 2005 [23], identifying 1486 proteins of culture-derived 
trypomastigotes, and 30 trans-sialidases, enzymes that play an important role 
in parasite host cell invasion, were among the top-scoring proteins exclusively 
detected in this developmental form. T. cruzi surface subproteome and basic 
proteins analysis confirmed the high distribution of trans-sialidases in this life 
form [154, 155]. Specific trypomastigote surface analysis also revealed membrane-
associated enzymes that are involved in biosynthetic pathway of phospholipid 
and glycolysis [155]. The evaluation of chromatin fraction of this stage revealed 
RNA-binding proteins and histones, representing 29% of chromatin protein content 
[156], providing new insights into gene expression and histone modifications 
involved in the parasite cycle regulation. Likewise, T. cruzi glycoproteome was 
assessed, and trypomastigote-specific glycoproteins were identified, including 
mucin family members [157, 158].
In metacyclic trypomastigotes, Atwood and co-workers [23] identified 2339 
proteins, and different antioxidant enzymes were among the main proteins 
detected. The presence of these enzymes in this stage could be related to the para-
site adaptation to the oxidative environment inside the vertebrate host circulation 
and particularly inside the phagocytes. The analysis of metacyclogenesis revealed 
increased expression of cytoskeletal proteins as well as proteins related to energetic 
and oxidative metabolisms, suggestive of the morphological and metabolic reor-
ganization [159]. Plasma membrane subproteome pointed to a large repertoire of 
surface proteins in this parasite stage, including trans-sialidases, mucins, and GP63 
protease [160]. Such glycoprotein diversity confers adaptation of the parasite to 
distinct environmental conditions. Morever, secretome of metacyclic trypomasti-
gotes also demonstrated trans-sialidases and other surface molecules, playing a role 
in parasite invasion during acute and chronic infections [161, 162]. The blockage of 
this process could be an interesting strategy in novel drug development.
The first proteomic analysis of bloodstream trypomastigotes was performed by 
our group in 2015, identifying a total 5901 proteins [163]. In this work, a compari-
son among the proteomic maps of trypomastigotes (bloodstream, cultured-derived, 
and metacyclic forms) was also assessed, and 2202 proteins related to the parasite 
surface, cytoskeleton, redox metabolism, cell signaling, and energetic metabolism 
were exclusively detected in bloodstream forms. Overall, the proteomic profile 
of bloodstream form comprises an important tool to discover potential new drug 
targets and novel antigens for vaccines or diagnostics. The differences in the 
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trypomastigote proteomic profiles were expected due to their environment, and 
huge number of stage-specific proteins in bloodstream forms, probably triggered by 
the exposure to the host immune system reinforces the necessity for drug validation 
on this developmental form. In relation to proteomic evaluation of trypanocidal 
action of drugs, β-lapachone-derived naphthoimidazoles induced the increase in 
the abundance of 27 proteins, involved in stress response, cell structure, energetic 
metabolism, nucleic and amino acid metabolisms, oxidative metabolism, among 
other pathways [164]. This large-scale study revealed an important set of proteins 
belonging to metabolic pathways that play pivotal functions for this parasite form, 
providing new insights for the understanding of the parasite biology and of poten-
tial drugable molecules for the treatment of Chagas disease.
In 2005, 1871 proteins of culture-derived amastigotes were identified, prefer-
ably involved in endoplasmic reticulum to Golgi trafficking, suggesting an intense 
traffic at this stage [23]. The analysis of amastigogenesis evidenced high abundance 
of glycolytic enzymes in amastigotes as well as the lower abundance of flagellar 
components, compatible with the morphology of this stage [165]. Later, the surface 
subproteome of vertebrate-dwelling parasite forms was characterized, displaying 
molecules involved in cell division, signal transduction, and lipid metabolism, 
crucial for the parasite intracellular self-maintenance [155].
Another interesting target is the posttranslational modification of parasite 
proteins. Acetylation at lysine residues exerts important role in both vertebrates 
and microbial cells. The NAD+-dependent lysine deacetylases are termed sirtuins. 
Humans present seven different sirtuins, whereas T. cruzi, solely two. TcSIR2RP1 
andTcSIR2RP3 are found in the cytosolic and mitochondrial compartments, respec-
tively. Parasites overexpressing TcSIR2RP1 display enhanced metacyclogenesis and 
host cell infection [166]. The sirtuin antagonist salermide diminishes intracellular 
parasite proliferation and parasitemia in murine infection [167]. Thus, acetylation 
of T. cruzi proteins may provide useful targets for the development of antiparasitic 
agents [167, 168]. In addition, mammalian sirtuin targeting may be beneficial in 
chronic chagasic cardiomyopathy [169].
4. Conclusions
The clinical chemotherapy for Chagas disease (Nif and Bz) led to a parasitologi-
cal cure in the great number of congenital, adult acute, or early chronic cases [170]. 
However, undesirable side effects and the resistance of some parasite strains [171], 
together with the limited efficacy in symptomatic chronic cases, drive the continu-
ous search for novel chemotherapeutic agents [33]. Drug repurposing or even 
combinations with the current drugs could be options to minimize this problem [59, 
120]. In this direction, phenotypic strategy has been considered the most valuable 
approach for the screening of antiparasitic compounds [172].
High throughput screening complemented by whole-cell phenotypic assays 
represents the more feasible option in the search for novel anti-T. cruzi compounds, 
also leading to an increment in sensitivity [173]. Preclinical in silico combined to in 
vitro assays represents an essential step for the recognition of T. cruzi drug targets, 
generating knowledge about the metabolism, biochemical pathways, or biological 
processes allowing the target validation. In this way, the identification of selective 
targets comprises a logical startpoint to the reduction of the side effects in the hosts 
[153, 163]. Ultrastructural observations can predict the potential primary cellular 
targets due to their earlier alterations triggered by pharmacologic stimuli, helping 
the prospection of molecular modes of action of antiparasitic agents [141, 174].
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Large-scale proteomics represents an alternative approach for the assessment 
of molecular mechanisms of trypanocidal drugs. Indeed, despite its potential, such 
technique is poorly employed in this context. The importance of the use of clinical 
relevant T. cruzi stages in drug screening was evidenced by the remarkable differ-
ences found among the proteomic profile of parasite forms [23, 163]. The proteomic 
analysis of bloodstream trypomastigotes identified a huge variety of proteins from 
distinct biological processes, pointed to more than 2000 proteins present only in 
bloodstream forms (not in trypomastigotes from other sources), reinforcing the 
importance of the chemotherapeutic tests using recent isolated parasites from 
animals’ blood [163].
In the current scenario, the CYP51 still represents one the most promising 
alternatives. Large-scale screening pointed to the high activity of CYP51 inhibitors 
in vitro (even higher than Bz), but not producing T. cruzi elimination [175, 176]. 
Unfortunately, the clinical trial with posaconazole and E1224 was also unsatisfac-
tory [102]. In Argentina, a drug–drug interaction analysis of the combination Bz 
and E1224 in healthy volunteers demonstrated no improvement in tolerability or 
safety parameters [177], and a clinical study using this combination is planned 
[178]. Also, the use of new scaffolds with the design of inhibitors much more selec-
tive toward CYP51 has demonstrated its high trypanocidal activity in association or 
not with other licensed drugs [108, 179].
Among the parasite antioxidant defenses, the most promising drug target is TR, 
and the specific inhibitor development has been proposed in the last three decades 
[36]. However, no active inhibitors of this enzyme were described up to now 
[180]. The hypothesis that T. cruzi is more susceptible to oxidative species than the 
vertebrate hosts is an old misleading concept, due to the highly efficient scavengers 
described in the parasite [51, 181]. Another aspect to be considered is the central 
role of ROS production and the mitochondrion for the trypanocial action of a great 
variety of preclinical compounds [31]. The mitochondrial swelling is frequently 
observed in T. cruzi after the treatment with different drugs, but this phenotype is 
rarely associated with a specific molecular mechanism, except for DNA ligands such 
as aromatic amidines [106]. The molecular mechanistic proposal opens the possibil-
ity of the mitochondrial dysfunction to be as a random consequences of indirect 
effect triggered by the impaired homeostasis, resulting in redox imbalance [31].
Bioinformatic, proteomic, and ultrastructural analyses are pivotal tools in the 
identification of drug targets; however, the use of specific inhibitors must be vali-
dated before the following studies. The absence of the predicted biological activity 
or even the specific binding to the respective molecular target is not uncommon 
[178, 182]. To improve the safety, mechanisms of action characterization should be 
performed in parallel to the high-throughput screening of the trypanocidal activity 
[183]. In case of obligatory intracellular parasites as T. cruzi, the direct analysis in a 
phenotypic assay is also essential, considering permeability of the host cells besides 
the therapeutic window related to the mammalian host toxicity aspects [182]. The 
adequate choice of the experimental design is also crucial. Animal models, parasite 
strains, and treatment protocols for preclinical assays (in vitro and in vivo) must be 
standardized, in order to reach better translation to humans [184].
Acknowledgements
This research was funded by grants from the Conselho Nacional de 
Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa 
do Rio de Janeiro (Faperj) and by Fundação Oswaldo Cruz (Fiocruz).
Biology of Trypanosoma cruzi
14
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Marcos André Vannier-Santos1, Giselle V. Brunoro2, Maria de Nazaré C. Soeiro3, 
Solange L. DeCastro3 and Rubem F.S. Menna-Barreto3*
1 Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil
2 Centre of Excellence in New Target Discovery, Butantan Institute,  
São Paulo, Brazil
3 Laboratory of Cellular Biology Cellular, Oswaldo Cruz Institute, FIOCRUZ,  
Rio de Janeiro, Brazil
*Address all correspondence to: rubemsadok@gmail.com
Conflict of interest
None to declare.
15
Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease
DOI: http://dx.doi.org/10.5772/intechopen.84472
References
[1] Dias JCP, Ramos AN Jr, Gontijo ED,  
Luquetti A, Shikanai-Yasuda MA, 
Coura JR, et al. 2 nd Brazilian 
consensus on Chagas disease, 2015. 
Revista da Sociedade Brasileira de 
Medicina Tropical. 2016;49:3-60. DOI: 
10.1590/0037-8682-0505-2016
[2] WHOChagas disease in Latin 
America: An epidemiological update 
based on 2010 estimates. Relevé 
Épidémiologique Hebdomadaire. 
2015;90:33-43
[3] Schmunis GA. Epidemiology 
of Chagas disease in non-endemic 
countries: The role of international 
migration. Memórias do Instituto 
Oswaldo Cruz. 2007;102(Suppl 1): 
75-85. DOI: 10.1590/S0074- 
02762007005000093
[4] Antinori S, Galimberti L, Bianco R,  
Grande R, Galli M, Corbellino M.  
Chagas disease in Europe: A review 
for the internist in the globalized 
world. European Journal of Internal 
Medicine. 2017;43:6-15. DOI: 10.1016/j.
ejim.2017.05.001
[5] Monge-Maillo B, López-Vélez R.  
Challenges in the management of 
Chagas disease in Latin-American 
migrants in Europe. Clinical 
Microbiology and Infection. 
2017;23:290-295. DOI: 10.1016/j.
cmi.2017.04.013
[6] Messenger LA, Bern C. Congenital 
Chagas disease: Current diagnostics, 
limitations and future perspectives. 
Current Opinion in Infectious Diseases. 
2018;31:415, 421. DOI: 10.1097/
QCO.0000000000000478
[7] Carlier Y, Torrico F, Sosa-Estani S,  
Russomando G, Luquetti A, Freilij H,  
et al. Congenital Chagas disease: 
Recommendations for diagnosis, 
treatment and control of newborns, 
siblings and pregnant women. 
PLoS Neglected Tropical Diseases. 
2011;5:e1250. DOI: 10.1371/journal.
pntd.0001250
[8] Shikanai-Yasuda MA, Carvalho NB.  
Oral transmission of Chagas disease. 
Clinical Infectious Diseases. 2012;54: 
845-852. DOI: 10.1093/cid/cir956
[9] Silva-dos-Santos D, Barreto-de-
Albuquerque J, Guerra B, Moreira OC, 
Berbert LR, Ramos MT, et al. Unraveling 
Chagas disease transmission through 
the oral route: Gateways to Trypanosoma 
cruzi infection and target tissues. 
PLoS Neglected Tropical Diseases. 
2017;11:e0005507. DOI: 10.1371/journal.
pntd.0005507
[10] Centers for Disease Control and 
Prevention. Congenital transmission 
of Chagas disease—Virginia, 2010. 
Morbidity and Mortality Weekly Report. 
2012;61:477-479
[11] Rodari P, Angheben A, Gennati G, 
Trezzi L, Bargiggia G, Maino M, et al. 
Congenital Chagas disease in a non-
endemic area: Results from a control 
programme in Bergamo province, 
Northern Italy. Travel Medicine and 
Infectious Disease. 2018;25:31-34. DOI: 
10.1016/j.tmaid.2018.04.011
[12] Coura JR, Junqueira AC.  
Surveillance, health promotion and 
control of Chagas disease in the 
Amazon region—Medical attention 
in the Brazilian Amazon region: A 
proposal. Memórias do Instituto 
Oswaldo Cruz. 2015;110:825-830. DOI: 
10.1590/0074-02760150153
[13] Ferreira RTB, Cabral ML, Martins 
RS, Araujo PF, da Silva SA, Britto C,  
et al. Detection and genotyping 
of Trypanosoma cruzi from açai 
products commercialized in Rio de 
Janeiro and Pará, Brazil. Parasites 
& Vectors. 2018;11. DOI: 10.1186/
s13071-018-2699-6
Biology of Trypanosoma cruzi
16
[14] WHO, editor. Control of Chagas 
Disease: Second Report of the WHO 
Expert Committee. Geneva: WHO; 2002
[15] Prata A. Clinical and 
epidemiological aspects of Chagas 
disease. The Lancet Infectious 
Diseases. 2001;1:92-100. DOI: 10.1016/
S1473-3099(01)00065-2
[16] FDA. FDA approves first U.S. 
treatment for Chagas disease. US Food 
Drug Adm; 2017. Available from: https://
www.fda.gov/newsevents/newsroom/
pressannouncements/ucm573942.htm 
[Accessed: September 20, 2018]
[17] Coura J, de Castro SL. A critical 
review on Chagas disease chemotherapy. 
Memórias do Instituto Oswaldo 
Cruz. 2002;97:3-24. DOI: 10.1590/
S0074-02762002000100001
[18] Coura JR, Borges-Pereira J. Chronic 
phase of Chagas disease: Why should 
it be treated? A comprehensive review. 
Memórias do Instituto Oswaldo Cruz. 
2011;106:641-645
[19] Jackson Y, Alirol E, Getaz L, 
Wolff H, Combescure C, Chappuis 
F. Tolerance and safety of Nifurtimox 
in patients with chronic Chagas 
disease. Clinical Infectious Diseases. 
2010;51:e69-e75. DOI: 10.1086/656917
[20] Sperandio da Silva GM, Mediano 
MFF, Alvarenga Americano do Brasil 
PE, da Costa Chambela M, da Silva JA, 
de Sousa AS, et al. A clinical adverse 
drug reaction prediction model for 
patients with Chagas disease treated 
with benznidazole. Antimicrobial 
Agents and Chemotherapy. 
2014;58:6371-6377. DOI: 10.1128/
AAC.02842-14
[21] Pérez-Molina JA, Molina I. Chagas 
disease. The Lancet. 2018;391:82-94. 
DOI: 10.1016/S0140-6736(17)31612-4
[22] Rassi A Jr, Marin Neto JA, Rassi 
A. Chronic Chagas cardiomyopathy: 
A review of the main pathogenic 
mechanisms and the efficacy of 
aetiological treatment following 
the BENznidazole evaluation for 
interrupting Trypanosomiasis 
(BENEFIT) trial. Memórias do Instituto 
Oswaldo Cruz. 2017;112:224-235. DOI: 
10.1590/0074-02760160334
[23] Atwood JA, Weatherly DB, Minning 
TA, Bundy B, Cavola C, Opperdoes FR, 
et al. The Trypanosoma cruzi proteome. 
Science. 2005;309:473-476. DOI: 
10.1126/science.1110289
[24] Gonçalves RLS, Barreto RFSM, 
Polycarpo CR, Gadelha FR, Castro 
SL, Oliveira MF. A comparative 
assessment of mitochondrial function 
in epimastigotes and bloodstream 
trypomastigotes of Trypanosoma 
cruzi. Journal of Bioenergetics and 
Biomembranes. 2011;43:651-661. DOI: 
10.1007/s10863-011-9398-8
[25] Venditti P, Di Stefano L, Di Meo S.  
Mitochondrial metabolism of reactive 
oxygen species. Mitochondrion. 
2013;13:71-82. DOI: 10.1016/j.
mito.2013.01.008
[26] Bombaça ACS, Menna-Barreto RFS.  
The oxidative metabolism in 
trypanosomatids: Implications for 
these protozoa biology and perspectives 
for drugs development. In: Leon L, 
Torres-Santos EC, editors. Differ. Asp. 
Chemother. Trypanos. First. New York: 
Nova Science Publishers; 2017. 
pp. 93-129
[27] Beltran-Hortelano I, Perez-Silanes 
S, Galiano S. Trypanothione reductase 
and superoxide dismutase as current 
drug targets for Trypanosoma cruzi: 
An overview of compounds with 
activity against Chagas disease. Current 
Medicinal Chemistry. 2017;24:1066-
1138. DOI: 10.2174/09298673236661612
27094049
[28] Boveris A, Hertig CM, Turrens JF.  
Fumarate reductase and other 
17
Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease
DOI: http://dx.doi.org/10.5772/intechopen.84472
mitochondrial activities in Trypanosoma 
cruzi. Molecular and Biochemical 
Parasitology. 1986;19:163-169
[29] Coustou V, Besteiro S, Rivière L, 
Biran M, Biteau N, Franconi J-M, et al. 
A mitochondrial NADH-dependent 
fumarate reductase involved in the 
production of succinate excreted by 
procyclic Trypanosoma brucei. The 
Journal of Biological Chemistry. 
2005;280:16559-16570. DOI: 10.1074/
jbc.M500343200
[30] Mehta A, Shaha C. Apoptotic death 
in Leishmania donovani promastigotes 
in response to respiratory chain 
inhibition: Complex II inhibition results 
in increased pentamidine cytotoxicity. 
The Journal of Biological Chemistry. 
2004;279:11798-11813. DOI: 10.1074/
jbc.M309341200
[31] Menna-Barreto RFS, de Castro 
SL. The double-edged sword in 
pathogenic trypanosomatids: The 
pivotal role of mitochondria in oxidative 
stress and bioenergetics. BioMed 
Research International. 2014;2014:1-14. 
DOI: 10.1155/2014/614014
[32] Barros-Alvarez X, Gualdrón-López 
M, Acosta H, Cáceres AJ, Graminha 
MAS, Michels PAM, et al. Glycosomal 
targets for anti-trypanosomatid 
drug discovery. Current Medicinal 
Chemistry. 2014;21:1679-1706. DOI: 
10.2174/09298673113209990139
[33] Menna-Barreto RFS, d CSL. Clear 
shot at primary aim: Susceptibility 
of Trypanosoma cruzi organelles, 
structures and molecular targets to drug 
treatment. Current Topics in Medicinal 
Chemistry. 2016;17:1212-1234. DOI: 10.2
174/1568026616666161025161858
[34] Hernandez FR, Turrens JF. 
Rotenone at high concentrations 
inhibits NADH-fumarate reductase 
and the mitochondrial respiratory 
chain of Trypanosoma brucei and 
T. cruzi. Mol Biochem Parasitol. 
1998;93:135-137. DOI: 10.1016/
S0166-6851(98)00015-2
[35] Fairlamb AH, Blackburn P, Ulrich 
P, Chait BT, Cerami A. Trypanothione: 
A novel bis(glutathionyl)spermidine 
cofactor for glutathione reductase 
in trypanosomatids. Science. 
1985;227:1485-1487
[36] Leroux AE, Krauth-Siegel RL. Thiol 
redox biology of trypanosomatids and 
potential targets for chemotherapy. 
Molecular and Biochemical Parasitology. 
2016;206:67-74. DOI: 10.1016/j.
molbiopara.2015.11.003
[37] Krieger S, Schwarz W, 
Ariyanayagam MR, Fairlamb AH,  
Krauth-Siegel RL, Clayton C.  
Trypanosomes lacking trypanothione 
reductase are avirulent and show 
increased sensitivity to oxidative 
stress. Molecular Microbiology. 
2000;35:542-552
[38] Krauth-Siegel RL, Bauer H, 
Schirmer RH. Dithiol proteins as 
guardians of the intracellular redox 
milieu in parasites: Old and new drug 
targets in trypanosomes and malaria-
causing plasmodia. Angewandte 
Chemie, International Edition. 
2005;44:690-715. DOI: 10.1002/
anie.200300639
[39] Flohé L. The trypanothione system 
and its implications in the therapy of 
trypanosomatid diseases. International 
Journal of Medical Microbiology. 
2012;302:216-220. DOI: 10.1016/j.
ijmm.2012.07.008
[40] Maya JD, Salas CO, Aguilera-
Venegas B, Diaz MV, López-Muñoz 
R. Key proteins in the polyamine-
trypanothione pathway as drug targets 
against Trypanosoma cruzi. Current 
Medicinal Chemistry. 2014;21:1757-1771
[41] Beig M, Oellien F, Garoff L, 
Noack S, Krauth-Siegel RL, Selzer 
Biology of Trypanosoma cruzi
18
PM. Trypanothione reductase: A 
target protein for a combined in vitro 
and in silico screening approach. 
PLoS Neglected Tropical Diseases. 
2015;9:e0003773. DOI: 10.1371/journal.
pntd.0003773
[42] Vázquez K, Paulino M, Salas 
CO, Zarate-Ramos JJ, Vera B, Rivera 
G. Trypanothione reductase: A 
target for the development of anti-
Trypanosoma cruzi drugs. Mini Reviews 
in Medicinal Chemistry. 2017;17:939-
946. DOI: 10.2174/138955751766617031
5145410
[43] Talevi A, Carrillo C, Comini 
MA. The thiol-polyamine metabolism 
of Trypanosoma cruzi: Molecular targets 
and drug repurposing strategies. 
Current Medicinal Chemistry. 2018;25. 
DOI: 10.2174/0929867325666180926151
059. [Epub ahead of print]
[44] Ilari A, Genovese I, Fiorillo F, 
Battista T, DII, Fiorillo A, et al. Toward 
a drug against all kinetoplastids: 
From LeishBox to specific and 
potent trypanothione reductase 
inhibitors. Molecular Pharmaceutics. 
2018;15:3069-3078. DOI: 10.1021/acs.
molpharmaceut.8b00185
[45] Docampo R, Gadelha FR, Moreno 
SN, Benaim G, Hoffmann ME, Vercesi 
AE. Disruption of Ca2+ homeostasis in 
Trypanosoma cruzi by crystal violet. The 
Journal of Eukaryotic Microbiology. 
1993;40:311-316
[46] Monks TJ, Jones DC. The 
metabolism and toxicity of quinones, 
quinonimines, quinone methides, and 
quinone-thioethers. Current Drug 
Metabolism. 2002;3:425-438
[47] Salas CO, Faúndez M, Morello 
A, Maya JD, Tapia RA. Natural and 
synthetic naphthoquinones active 
against Trypanosoma cruzi: An initial 
step towards new drugs for Chagas 
disease. Current Medicinal Chemistry. 
2011;18:144-161
[48] Schmidt TJ, Khalid SA, Romanha 
AJ, Alves TM, Biavatti MW, Brun 
R, et al. The potential of secondary 
metabolites from plants as drugs or 
leads against protozoan neglected 
diseases—Part II. Current Medicinal 
Chemistry. 2012;19:2176-2228
[49] da Silva Júnior EN, Jardim GAM, 
Menna-Barreto RFS, de Castro SL. Anti-
Trypanosoma cruzi compounds: Our 
contribution for the evaluation and 
insights on the mode of action of 
naphthoquinones and derivatives. 
Journal of the Brazilian Chemical 
Society. 2014;25:1780-1798. DOI: 
10.5935/0103-5053.20140180
[50] Pieretti S, Haanstra JR, Mazet M, 
Perozzo R, Bergamini C, Prati F, et al. 
Naphthoquinone derivatives exert their 
Antitrypanosomal activity via a multi-
target MECHANISM. PLoS Neglected 
Tropical Diseases. 2013;7:e2012. DOI: 
10.1371/journal.pntd.0002012
[51] Boveris A, Stoppani AOM.  
Hydrogen peroxide generation in 
Trypanosoma cruzi. Experientia. 
1977;33:1306-1308. DOI: 10.1007/
BF01920148
[52] Cruz FS, Docampo R, de Souza 
W. Effect of beta-lapachone on 
hydrogen peroxide production in 
Trypanosoma cruzi. Acta Tropica. 
1978;35:35-40
[53] Lara LS, Moreira CS, Calvet CM, 
Lechuga GC, Souza RS, Bourguignon 
SC, et al. Efficacy of 2-hydroxy-
3-phenylsulfanylmethyl-[1,4]-
naphthoquinone derivatives against 
different Trypanosoma cruzi discrete 
type units: Identification of a promising 
hit compound. European Journal of 
Medicinal Chemistry. 2018;144:572-581. 
DOI: 10.1016/j.ejmech.2017.12.052
[54] Menna-Barreto RFS, Goncalves 
RLS, Costa EM, Silva RSF, Pinto AV, 
Oliveira MF, et al. The effects on 
Trypanosoma cruzi of novel synthetic 
19
Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease
DOI: http://dx.doi.org/10.5772/intechopen.84472
naphthoquinones are mediated 
by mitochondrial dysfunction. 
Free Radical Biology & Medicine. 
2009;47:644-653. DOI: 10.1016/j.
freeradbiomed.2009.06.004
[55] Soares ROA, Echevarria A, 
Bellieny MSS, Pinho RT, de Leo 
RMM, Seguins WS, et al. Evaluation 
of thiosemicarbazones and 
semicarbazones as potential agents 
anti-Trypanosoma cruzi. Experimental 
Parasitology. 2011;129:381-387. DOI: 
10.1016/j.exppara.2011.08.019
[56] Martins SC, Lazarin-Bidóia 
D, Desoti VC, Falzirolli H, da 
Silva CC, Ueda-Nakamura T, et al. 
1,3,4-Thiadiazole derivatives of 
R-(+)-limonene benzaldehyde-
thiosemicarbazones cause death in 
Trypanosoma cruzi through oxidative 
stress. Microbes and Infection. 
2016;18:787-797. DOI: 10.1016/j.
micinf.2016.07.007
[57] Lapier M, Zuniga-Lopez MC, 
Aguilera-Venegas B, Adam R, Abarca 
B, Ballesteros R, et al. Evaluation of the 
novel antichagasic activity of [1,2,3]
Triazolo[1,5-a]pyridine derivatives. 
Current Topics in Medicinal Chemistry. 
2017;17:399-411
[58] Patterson S, Wyllie S. Nitro drugs 
for the treatment of trypanosomatid 
diseases: Past, present, and future 
prospects. Trends in Parasitology. 
2014;30:289-298. DOI: 10.1016/j.
pt.2014.04.003
[59] Bahia MT, Diniz L d F, 
Mosqueira VCF. Therapeutical 
approaches under investigation 
for treatment of Chagas disease. 
Expert Opinion on Investigational 
Drugs. 2014;23:1225-1237. DOI: 
10.1517/13543784.2014.922952
[60] DNDi. Fexinidazole (Chagas). 
Drugs Neglected Dis Initiat DNDi. 2018. 
Available from: https://www.dndi.org/
diseases-projects/portfolio/fexinidazole-
chagas [Accessed: November 2, 2018]
[61] Docampo R, Moreno SN. Free 
radical metabolites in the mode of 
action of chemotherapeutic agents 
and phagocytic cells on Trypanosoma 
cruzi. Reviews of Infectious Diseases. 
1984;6:223-238
[62] Peterson FJ, Mason RP, Hovsepian 
J, Holtzman JL. Oxygen-sensitive 
and -insensitive nitroreduction 
by Escherichia coli and rat hepatic 
microsomes. The Journal of Biological 
Chemistry. 1979;254:4009-4014
[63] Fairlamb AH, Patterson S. 
Current and future prospects of 
nitro-compounds as drugs for 
Trypanosomiasis and Leishmaniasis. 
Current Medicinal Chemistry. 2018;25. 
DOI: 10.2174/0929867325666180426164
352. [Epub ahead of print]
[64] Boiani M, Piacenza L, Hernández 
P, Boiani L, Cerecetto H, González M, 
et al. Mode of action of nifurtimox and 
N-oxide-containing heterocycles against 
Trypanosoma cruzi: Is oxidative stress 
involved? Biochemical Pharmacology. 
2010;79:1736-1745. DOI: 10.1016/j.
bcp.2010.02.009
[65] Hall BS, Wilkinson SR. Activation 
of benznidazole by trypanosomal type 
I nitroreductases results in glyoxal 
formation. Antimicrobial Agents and 
Chemotherapy. 2012;56:115-123. DOI: 
10.1128/AAC.05135-11
[66] Papadopoulou MV, Bloomer WD, 
Rosenzweig HS, O’Shea IP, Wilkinson 
SR, Kaiser M, et al. Discovery of potent 
nitrotriazole-based antitrypanosomal 
agents: In vitro and in vivo evaluation. 
Bioorganic & Medicinal Chemistry. 
2015;23:6467-6476. DOI: 10.1016/j.
bmc.2015.08.014
[67] Vannier-Santos MA, Suarez-Fontes 
AM. Role of polyamines in parasite 
cell architecture and function. Current 
Pharmaceutical Design. 2017;23:3342-
3358. DOI: 10.2174/13816128236661707
03163458
Biology of Trypanosoma cruzi
20
[68] Roberts S, Ullman B. Parasite 
polyamines as pharmaceutical targets. 
Current Pharmaceutical Design. 
2017;23:3325-3341. DOI: 10.2174/138161
2823666170601101644
[69] Algranati ID. Polyamine metabolism 
in Trypanosoma cruzi: Studies on 
the expression and regulation of 
heterologous genes involved in 
polyamine biosynthesis. Amino 
Acids. 2010;38:645-651. DOI: 10.1007/
s00726-009-0425-6
[70] Hasne M-P, Coppens I, Soysa 
R, Ullman B. A high-affinity 
putrescine-cadaverine transporter 
from Trypanosoma cruzi. Molecular 
Microbiology. 2010;76:78-91. DOI: 
10.1111/j.1365-2958.2010.07081.x
[71] Reigada C, Phanstiel O, Miranda 
MR, Pereira CA. Targeting polyamine 
transport in Trypanosoma cruzi. 
European Journal of Medicinal 
Chemistry. 2018;147:1-6. DOI: 10.1016/j.
ejmech.2018.01.083
[72] Díaz MV, Miranda MR, Campos-
Estrada C, Reigada C, Maya JD, Pereira 
CA, et al. Pentamidine exerts in vitro 
and in vivo anti Trypanosoma cruzi 
activity and inhibits the polyamine 
transport in Trypanosoma cruzi. Acta 
Tropica. 2014;134:1-9. DOI: 10.1016/j.
actatropica.2014.02.012
[73] Hasne M-P, Soysa R, Ullman B. The 
Trypanosoma cruzi diamine transporter 
is essential for robust infection 
of mammalian cells. PLoS One. 
2016;11:e0152715. DOI: 10.1371/journal.
pone.0152715
[74] Reigada C, Sayé M, Vera EV, 
Balcazar D, Fraccaroli L, Carrillo C, 
et al. Trypanosoma cruzi polyamine 
transporter: Its role on parasite growth 
and survival under stress conditions. 
The Journal of Membrane Biology. 
2016;249:475-481. DOI: 10.1007/
s00232-016-9888-z
[75] Mesías AC, Sasoni N, Arias 
DG, Pérez Brandán C, Orban OCF, 
Kunick C, et al. Trypanothione 
synthetase confers growth, survival 
advantage and resistance to anti-
protozoal drugs in Trypanosoma cruzi. 
Free Radical Biology & Medicine. 
2019;130:23-34. DOI: 10.1016/j.
freeradbiomed.2018.10.436
[76] Soares CO, Colli W, Bechara EJH, 
Alves MJM. 1,4-Diamino-2-butanone, 
a putrescine analogue, promotes 
redox imbalance in Trypanosoma 
cruzi and mammalian cells. Archives 
of Biochemistry and Biophysics. 
2012;528:103-110. DOI: 10.1016/j.
abb.2012.09.005
[77] Menezes D, Valentim C, Oliveira 
MF, Vannier-Santos MA. Putrescine 
analogue cytotoxicity against 
Trypanosoma cruzi. Parasitology 
Research. 2006;98:99-105. DOI: 10.1007/
s00436-005-0010-1
[78] Reis IA, Martinez MP, Yarlett N, 
Johnson PJ, Silva-Filho FC, Vannier-
Santos MA. Inhibition of polyamine 
synthesis arrests trichomonad 
growth and induces destruction of 
hydrogenosomes. Antimicrobial Agents 
and Chemotherapy. 1999;43:1919-1923
[79] Vannier-Santos MA, Menezes D,  
Oliveira MF, de Mello FG. The 
putrescine analogue 1,4-diamino-2-
butanone affects polyamine synthesis, 
transport, ultrastructure and 
intracellular survival in Leishmania 
amazonensis. Microbiology. 
2008;154:3104-3111. DOI: 10.1099/
mic.0.2007/013896-0
[80] Hernández SM, Sánchez MS, de 
Tarlovsky MNS. Polyamines as a defense 
mechanism against lipoperoxidation 
in Trypanosoma cruzi. Acta Tropica. 
2006;98:94-102. DOI: 10.1016/j.
actatropica.2006.02.005
[81] Vanrell MC, Losinno AD, Cueto 
JA, Balcazar D, Fraccaroli LV, Carrillo 
21
Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease
DOI: http://dx.doi.org/10.5772/intechopen.84472
C, et al. The regulation of autophagy 
differentially affects Trypanosoma cruzi 
metacyclogenesis. PLoS Neglected 
Tropical Diseases. 2017;11:e0006049. 
DOI: 10.1371/journal.pntd.0006049
[82] Nes WD. Biosynthesis of cholesterol 
and other sterols. Chemical Reviews. 
2011;111:6423-6451. DOI: 10.1021/
cr200021m
[83] Leaver D. Synthesis and biological 
activity of sterol 14α-demethylase and 
sterol C24-methyltransferase inhibitors. 
Molecules. 2018;23:1753. DOI: 10.3390/
molecules23071753
[84] Lepesheva GI, Friggeri L, 
Waterman MR. CYP51 as drug targets 
for fungi and protozoan parasites: 
Past, present and future. Parasitology. 
2018;145:1820-1836. DOI: 10.1017/
S0031182018000562
[85] Do R, Kiss R, Gaudet D, Engert 
J. Squalene synthase: A critical enzyme 
in the cholesterol biosynthesis pathway. 
Clinical Genetics. 2009;75:19-29. DOI: 
10.1111/j.1399-0004.2008.01099.x
[86] Urbina JA, Concepcion JL, Rangel 
S, Visbal G, Lira R. Squalene synthase 
as a chemotherapeutic target in 
Trypanosoma cruzi and Leishmania 
mexicana. Molecular and Biochemical 
Parasitology. 2002;125:35-45
[87] Braga MV, Urbina JA, de Souza 
W. Effects of squalene synthase 
inhibitors on the growth and 
ultrastructure of Trypanosoma cruzi. 
International Journal of Antimicrobial 
Agents. 2004;24:72-78. DOI: 10.1016/j.
ijantimicag.2003.12.009
[88] Urbina JA, Concepcion JL, Caldera 
A, Payares G, Sanoja C, Otomo T, et al. 
In vitro and in vivo activities of E5700 
and ER-119884, two novel orally active 
squalene synthase inhibitors, against 
Trypanosoma cruzi. Antimicrobial 
Agents and Chemotherapy. 
2004;48:2379-2387. DOI: 10.1128/
AAC.48.7.2379-2387.2004
[89] Sealey-Cardona M, Cammerer S, 
Jones S, Ruiz-Perez LM, Brun R, Gilbert 
IH, et al. Kinetic characterization of 
squalene synthase from Trypanosoma 
cruzi: Selective inhibition by 
quinuclidine derivatives. Antimicrobial 
Agents and Chemotherapy. 
2007;51:2123-2129. DOI: 10.1128/
AAC.01454-06
[90] Shang N, Li Q, Ko T-P, Chan H-C, Li 
J, Zheng Y, et al. Squalene synthase As a 
target for Chagas disease therapeutics. 
PLoS Pathogens. 2014;10:e1004114. 
DOI: 10.1371/journal.ppat.1004114
[91] Rodriguez JB. WC-9 a Lead drug 
with great prospects for American 
Trypanosomiasis and Toxoplasmosis. 
Mini Reviews in Medicinal Chemistry. 
2016;16:1195-1200
[92] Urbina JA, Concepcion JL, 
Montalvetti A, Rodriguez JB, 
Docampo R. Mechanism of action of 
4-phenoxyphenoxyethyl thiocyanate 
(WC-9) against Trypanosoma 
cruzi, the causative agent of Chagas’ 
disease. Antimicrobial Agents and 
Chemotherapy. 2003;47:2047-2050
[93] Liñares GEG, Ravaschino EL, 
Rodriguez JB. Progresses in the field 
of drug design to combat tropical 
protozoan parasitic diseases. Current 
Medicinal Chemistry. 2006;13:335-360
[94] Chao MN, Storey M, Li C, 
Rodríguez MG, Di Salvo F, Szajnman 
SH, et al. Selenium-containing 
analogues of WC-9 are extremely 
potent inhibitors of Trypanosoma cruzi 
proliferation. Bioorganic & Medicinal 
Chemistry. 2017;25:6435-6449. DOI: 
10.1016/j.bmc.2017.10.016
[95] Urbina JA. Ergosterol biosynthesis 
and drug development for Chagas 
disease. Memórias do Instituto Oswaldo 
Cruz. 2009;104(Suppl 1):311-318
[96] Lepesheva GI, Villalta F, Waterman 
MR. Targeting Trypanosoma cruzi sterol 
Biology of Trypanosoma cruzi
22
14α-demethylase (CYP51). Advances 
in Parasitology. 2011;75:65-87. DOI: 
10.1016/B978-0-12-385863-4.00004-6
[97] Urbina JA, McKerrow JH. Drug 
susceptibility of genetically engineered 
Trypanosoma cruzi strains and sterile 
cure in animal models as a criterion 
for potential clinical efficacy of anti-T. 
cruzi drugs. Antimicrobial Agents and 
Chemotherapy. 2015;59:7923-7924. DOI: 
10.1128/AAC.01714-15
[98] Urbina JA, Payares G, Contreras 
LM, Liendo A, Sanoja C, Molina 
J, et al. Antiproliferative effects 
and mechanism of action of 
SCH 56592 against Trypanosoma 
(Schizotrypanum) cruzi: In vitro and 
in vivo studies. Antimicrobial Agents 
and Chemotherapy. 1998;42:1771-1777
[99] Molina J, Martins-Filho O, 
Brener Z, Romanha AJ, Loebenberg 
D, Urbina JA. Activities of the 
triazole derivative SCH 56592 
(posaconazole) against drug-resistant 
strains of the protozoan parasite 
Trypanosoma (Schizotrypanum) 
cruzi in immunocompetent and 
immunosuppressed murine 
hosts. Antimicrobial Agents and 
Chemotherapy. 2000;44:150-155
[100] Urbina JA, Payares G, Sanoja 
C, Lira R, Romanha AJ. In vitro and 
in vivo activities of ravuconazole on 
Trypanosoma cruzi, the causative agent 
of Chagas disease. International Journal 
of Antimicrobial Agents. 2003;21:27-38
[101] Diniz L de F, Caldas IS, Guedes PM 
da M, Crepalde G, de Lana M, Carneiro 
CM, et al. Effects of ravuconazole 
treatment on parasite load and immune 
response in dogs experimentally 
infected with Trypanosoma 
cruzi. Antimicrobial Agents and 
Chemotherapy. 2010;54:2979-2986. 
DOI: 10.1128/AAC.01742-09
[102] Molina I, Gómez i, Prat J, 
Salvador F, Treviño B, Sulleiro E, et al. 
Randomized trial of posaconazole 
and benznidazole for chronic Chagas’ 
disease. The New England Journal of 
Medicine. 2014;370:1899-1908. DOI: 
10.1056/NEJMoa1313122
[103] Morillo CA, Waskin H, Sosa-Estani 
S, del Carmen Bangher M, Cuneo 
C, Milesi R, et al. Benznidazole and 
Posaconazole in eliminating parasites in 
asymptomatic T. cruzi carriers. Journal 
of the American College of Cardiology. 
2017;69:939-947. DOI: 10.1016/j.
jacc.2016.12.023
[104] Torrico F, Gascon J, Ortiz L, 
Alonso-Vega C, Pinazo M-J, Schijman 
A, et al. Treatment of adult chronic 
indeterminate Chagas disease with 
benznidazole and three E1224 dosing 
regimens: A proof-of-concept, 
randomised, placebo-controlled 
trial. The Lancet Infectious Diseases. 
2018;18:419-430. DOI: 10.1016/
S1473-3099(17)30538-8
[105] Villalta F, Dobish MC, Nde PN, 
Kleshchenko YY, Hargrove TY, Johnson 
CA, et al. VNI cures acute and chronic 
experimental Chagas disease. The Journal 
of Infectious Diseases. 2013;208:504-511. 
DOI: 10.1093/infdis/jit042
[106] Soeiro M de NC, de Souza EM, 
da Silva CF, Batista D da GJ, Batista 
MM, Pavão BP, et al. In vitro and 
in vivo studies of the Antiparasitic 
activity of sterol 14α-demethylase 
(CYP51) inhibitor VNI against drug-
resistant strains of Trypanosoma 
cruzi. Antimicrobial Agents and 
Chemotherapy. 2013;57:4151-4163. DOI: 
10.1128/AAC.00070-13
[107] Lepesheva GI, Hargrove TY, 
Rachakonda G, Wawrzak Z, Pomel S, 
Cojean S, et al. VFV as a new effective 
CYP51 structure-derived drug candidate 
for Chagas disease and visceral 
Leishmaniasis. The Journal of Infectious 
Diseases. 2015;212:1439-1448. DOI: 
10.1093/infdis/jiv228
23
Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease
DOI: http://dx.doi.org/10.5772/intechopen.84472
[108] Guedes-da-Silva FH, Batista 
DGJ, Da Silva CF, De Araújo JS, 
Pavão BP, Simões-Silva MR, et al. 
Antitrypanosomal activity of 
sterol 14α-demethylase (CYP51) 
inhibitors VNI and VFV in the Swiss 
mouse models of Chagas disease 
induced by the Trypanosoma cruzi 
Y strain. Antimicrobial Agents and 
Chemotherapy. 2017;61:e02098-16. DOI: 
10.1128/AAC.02098-16
[109] Hoekstra WJ, Hargrove TY, 
Wawrzak Z, da Gama Jaen Batista 
D, da Silva CF, Nefertiti ASG, 
et al. Clinical candidate VT-1161’s 
antiparasitic effect in vitro, activity in 
a murine model of Chagas disease, and 
structural characterization in complex 
with the target enzyme CYP51 from 
Trypanosoma cruzi. Antimicrobial 
Agents and Chemotherapy. 
2016;60:1058-1066. DOI: 10.1128/
AAC.02287-15
[110] Friggeri L, Hargrove TY, 
Rachakonda G, Williams AD, 
Wawrzak Z, DSR, et al. Structural 
basis for rational design of inhibitors 
targeting Trypanosoma cruzi sterol 
14α-demethylase: Two regions of 
the enzyme molecule potentiate 
its inhibition. Journal of Medicinal 
Chemistry. 2014;57:6704-6717. DOI: 
10.1021/jm500739f
[111] De Vita D, Moraca F, Zamperini 
C, Pandolfi F, Di Santo R, Matheeussen 
A, et al. In vitro screening of 
2-(1H-imidazol-1-yl)-1-phenylethanol 
derivatives as antiprotozoal agents and 
docking studies on Trypanosoma cruzi 
CYP51. European Journal of Medicinal 
Chemistry. 2016;113:28-33. DOI: 
10.1016/j.ejmech.2016.02.028
[112] Ferreira de Almeida Fiuza L, 
Peres RB, Simões-Silva MR, da Silva 
PB, Batista D d GJ, da Silva CF, et al. 
Identification of Pyrazolo[3,4-e][1,4]
thiazepin based CYP51 inhibitors as 
potential Chagas disease therapeutic 
alternative: In vitro and in vivo 
evaluation, binding mode prediction 
and SAR exploration. European 
Journal of Medicinal Chemistry. 
2018;149:257-268. DOI: 10.1016/j.
ejmech.2018.02.020
[113] Ferreira LG, Andricopulo 
AD. Targeting cysteine proteases in 
trypanosomatid disease drug discovery. 
Pharmacology & Therapeutics. 
2017;180:49-61. DOI: 10.1016/j.
pharmthera.2017.06.004
[114] Siqueira-Neto JL, Debnath A, 
McCall L-I, Bernatchez JA, Ndao M, 
Reed SL, et al. Cysteine proteases in 
protozoan parasites. PLoS Neglected 
Tropical Diseases. 2018;12:e0006512. 
DOI: 10.1371/journal.pntd.0006512
[115] Martinez-Mayorga K, Byler KG, 
Ramirez-Hernandez AI, Terrazas-
Alvares DE. Cruzain inhibitors: Efforts 
made, current leads and a structural 
outlook of new hits. Drug Discovery 
Today. 2015;20:890-898. DOI: 10.1016/j.
drudis.2015.02.004
[116] Nicoll-Griffith DA. Use of 
cysteine-reactive small molecules 
in drug discovery for trypanosomal 
disease. Expert Opinion on Drug 
Discovery. 2012;7:353-366. DOI: 
10.1517/17460441.2012.668520
[117] Engel JC, Doyle PS, Hsieh I, 
McKerrow JH. Cysteine protease 
inhibitors cure an experimental 
Trypanosoma cruzi infection. The 
Journal of Experimental Medicine. 
1998;188:725-734
[118] Doyle PS, Zhou YM, Engel JC, 
McKerrow JH. A cysteine protease 
inhibitor cures Chagas’ disease in an 
Immunodeficient-mouse model of 
infection. Antimicrobial Agents and 
Chemotherapy. 2007;51:3932-3939. DOI: 
10.1128/AAC.00436-07
[119] Chen YT, Brinen LS, Kerr ID, 
Hansell E, Doyle PS, McKerrow JH, 
Biology of Trypanosoma cruzi
24
et al. In vitro and in vivo studies 
of the trypanocidal properties of 
WRR-483 against Trypanosoma cruzi. 
PLoS Neglected Tropical Diseases. 
2010;4:e825. DOI: 10.1371/journal.
pntd.0000825
[120] Salomão K, De Castro SL, editors. 
Recent Advances in Drug Development 
for Chagas Disease: Two Magic Words, 
Combination and Repositioning. Differ. 
Asp. Chemother. Trypanos. New York: 
Leon L & Torres-Santos EC; 2017. 
pp. 181-226
[121] Mott BT, Ferreira RS, Simeonov 
A, Jadhav A, Ang KK-H, Leister W, 
et al. Identification and optimization 
of inhibitors of trypanosomal cysteine 
proteases: Cruzain, Rhodesain, 
and TbCatB. Journal of Medicinal 
Chemistry. 2010;53:52-60. DOI: 10.1021/
jm901069a
[122] Beaulieu C, Isabel E, Fortier A, 
Massé F, Mellon C, Méthot N, et al. 
Identification of potent and reversible 
cruzipain inhibitors for the treatment of 
Chagas disease. Bioorganic & Medicinal 
Chemistry Letters. 2010;20:7444-7449. 
DOI: 10.1016/j.bmcl.2010.10.015
[123] Ndao M, Beaulieu C, Black WC, 
Isabel E, Vasquez-Camargo F, Nath-
Chowdhury M, et al. Reversible cysteine 
protease inhibitors show promise for 
a Chagas disease cure. Antimicrobial 
Agents and Chemotherapy. 
2014;58:1167-1178. DOI: 10.1128/
AAC.01855-13
[124] Burtoloso ACB, de Albuquerque 
S, Furber M, Gomes JC, Gonçalez C, 
Kenny PW, et al. Anti-trypanosomal 
activity of non-peptidic nitrile-
based cysteine protease inhibitors. 
PLoS Neglected Tropical Diseases. 
2017;11:e0005343. DOI: 10.1371/journal.
pntd.0005343
[125] Salas-Sarduy E, Landaburu LU, 
Karpiak J, Madauss KP, Cazzulo JJ, 
Agüero F, et al. Novel scaffolds for 
inhibition of Cruzipain identified from 
high-throughput screening of anti-
kinetoplastid chemical boxes. Scientific 
Reports. 2017;7:12073. DOI: 10.1038/
s41598-017-12170-4
[126] Pauli I, Ferreira LG, de Souza ML, 
Oliva G, Ferreira RS, Dessoy MA, et al. 
Molecular modeling and structure–
activity relationships for a series of 
benzimidazole derivatives as cruzain 
inhibitors. Future Medicinal Chemistry. 
2017;9:641-657. DOI: 10.4155/
fmc-2016-0236
[127] de Souza AS, de Oliveira MT, 
Andricopulo AD. Development of 
a pharmacophore for cruzain using 
oxadiazoles as virtual molecular 
probes: Quantitative structure-activity 
relationship studies. Journal of 
Computer-Aided Molecular Design. 
2017;31:801-816. DOI: 10.1007/
s10822-017-0039-0
[128] Kaiser M, Mäser P, Tadoori LP, 
Ioset J-R, Brun R. Antiprotozoal activity 
profiling of approved drugs: A starting 
point toward drug repositioning. PLoS 
One. 2015;10:e0135556. DOI: 10.1371/
journal.pone.0135556
[129] Bellera CL, Balcazar DE, Alberca 
L, Labriola CA, Talevi A, Carrillo 
C. Identification of levothyroxine 
antichagasic activity through computer-
aided drug repurposing. Scientific 
World Journal. 2014;2014:1-9. DOI: 
10.1155/2014/279618
[130] Bellera CL, Balcazar DE, 
Vanrell MC, Casassa AF, Palestro PH, 
Gavernet L, et al. Computer-guided 
drug repurposing: Identification of 
trypanocidal activity of clofazimine, 
benidipine and saquinavir. European 
Journal of Medicinal Chemistry. 
2015;93:338-348. DOI: 10.1016/j.
ejmech.2015.01.065
[131] Sbaraglini ML, Bellera CL, 
Fraccaroli L, Larocca L, Carrillo 
25
Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease
DOI: http://dx.doi.org/10.5772/intechopen.84472
C, Talevi A, et al. Novel cruzipain 
inhibitors for the chemotherapy of 
chronic Chagas disease. International 
Journal of Antimicrobial Agents. 
2016;48:91-95. DOI: 10.1016/j.
ijantimicag.2016.02.018
[132] Palos I, Lara-Ramirez EE, Lopez-
Cedillo JC, Garcia-Perez C, Kashif M, 
Bocanegra-Garcia V, et al. Repositioning 
FDA drugs as potential Cruzain 
inhibitors from Trypanosoma cruzi: 
Virtual screening, in vitro and in vivo 
studies. Molecules (Basel, Switzerland). 
2017;22:E1015. DOI: 10.3390/
molecules22061015
[133] Branquinha MH, Marinho FA, 
Sangenito LS, Oliveira SSC, Goncalves KC, 
Ennes-Vidal V, et al. Calpains: Potential 
targets for alternative chemotherapeutic 
intervention against human pathogenic 
trypanosomatids. Current Medicinal 
Chemistry. 2013;20:3174-3185
[134] Saez ME, Ramirez-Lorca R, Moron 
FJ, Ruiz A. The therapeutic potential of 
the calpain family: New aspects. Drug 
Discovery Today. 2006;11:917-923. DOI: 
10.1016/j.drudis.2006.08.009
[135] Donkor IO. An updated patent 
review of calpain inhibitors (2012-
2014). Expert Opinion on Therapeutic 
Patents. 2015;25:17-31. DOI: 
10.1517/13543776.2014.982534
[136] Ennes-Vidal V, Menna-Barreto 
RFS, Santos ALS, Branquinha MH, 
d’Avila-Levy CM. MDL28170, a calpain 
inhibitor, affects Trypanosoma cruzi 
metacyclogenesis, ultrastructure and 
attachment to Rhodnius prolixus 
midgut. PLoS One. 2011;6:e18371. DOI: 
10.1371/journal.pone.0018371
[137] Ennes-Vidal V, Menna-Barreto 
RFS, Santos ALS, Branquinha MH, 
d’Avila-Levy CM. Effects of the calpain 
inhibitor MDL28170 on the clinically 
relevant forms of Trypanosoma cruzi 
in vitro. The Journal of Antimicrobial 
Chemotherapy. 2010;65:1395-1398. DOI: 
10.1093/jac/dkq154
[138] Motta MCM. Kinetoplast 
as a potential chemotherapeutic 
target of trypanosomatids. 
Current Pharmaceutical Design. 
2008;14:847-854
[139] Soeiro M de NC, de Castro 
SL. Screening of potential anti-
Trypanosoma cruzi candidates: In vitro 
and in vivo studies. Open Medicinal 
Chemistry Journal. 2011;5:21-30. DOI: 
10.2174/1874104501105010021
[140] Delain E, Brack C, Riou G, 
Festy B. Ultrastructural alterations of 
Trypanosoma cruzi kinetoplast induced 
by the interaction of a trypanocidal 
drug (hydroxystilbamidine) with 
the kinetoplast DNA. Journal of 
Ultrastructure Research. 1971;37:200-218
[141] Vannier-Santos MA, De Castro 
SL. Electron microscopy in antiparasitic 
chemotherapy: A (close) view to a kill. 
Current Drug Targets. 2009;10:246-260. 
DOI: 10.2174/138945009787581168
[142] Girard RMBM, Crispim M, Stolić 
I, Damasceno FS, Santos da Silva M, 
Pral EMF, et al. An aromatic diamidine 
that targets kinetoplast DNA, impairs 
the cell cycle in Trypanosoma cruzi, 
and diminishes trypomastigote 
release from infected mammalian 
host cells. Antimicrobial Agents and 
Chemotherapy. 2016;60:5867-5877. DOI: 
10.1128/AAC.01595-15
[143] Balaña-Fouce R, Álvarez-Velilla 
R, Fernández-Prada C, García-Estrada 
C, Reguera RM. Trypanosomatids 
topoisomerase re-visited. New 
structural findings and role in drug 
discovery. International Journal 
for Parasitology: Drugs and Drug 
Resistance. 2014;4:326-337. DOI: 
10.1016/j.ijpddr.2014.07.006
[144] Podestá D, Stoppani A, Villamil 
SF. Inactivation of Trypanosoma 
cruzi and Crithidia fasciculata 
topoisomerase I by Fenton systems. 
Redox Report. 2003;8:357-363. DOI: 
10.1179/135100003225003366
Biology of Trypanosoma cruzi
26
[145] Wilson WD, Nguyen B, Tanious 
FA, Mathis A, Hall JE, Stephens CE, 
et al. Dications that target the DNA 
minor groove: Compound design and 
preparation, DNA interactions, cellular 
distribution and biological activity. 
Current Medicinal Chemistry—Anti-
Cancer Agents. 2005;5:389-408
[146] Werbovetz K. Diamidines as 
antitrypanosomal, antileishmanial  
and antimalarial agents. Current 
Opinion in Investigational Drugs 
(London, England: 2000). 
2006;7:147-157
[147] Silva CF, Meuser MB, De Souza 
EM, Meirelles MNL, Stephens CE, 
Som P, et al. Cellular effects of 
reversed amidines on Trypanosoma 
cruzi. Antimicrobial Agents and 
Chemotherapy. 2007;51:3803-3809. 
DOI: 10.1128/AAC.00047-07
[148] Silva CF, Batista MM, Mota 
RA, de Souza EM, Stephens CE, 
Som P, et al. Activity of “reversed” 
diamidines against Trypanosoma cruzi 
“in vitro”. Biochemical Pharmacology. 
2007;73:1939-1946. DOI: 10.1016/j.
bcp.2007.03.020
[149] Santos CC, Lionel JR, Peres RB, 
Batista MM, da Silva PB, de Oliveira 
GM, et al. In vitro, in silico, and 
in vivo analyses of novel aromatic 
amidines against Trypanosoma 
cruzi. Antimicrobial Agents and 
Chemotherapy. 2017;62:e02205-17. DOI: 
10.1128/AAC.02205-17
[150] Das A, Dasgupta A, Sengupta 
T, Majumder HK. Topoisomerases of 
kinetoplastid parasites as potential 
chemotherapeutic targets. Trends in 
Parasitology. 2004;20:381-387. DOI: 
10.1016/j.pt.2004.06.005
[151] Chowdhury SR, Godinho JLP, 
Vinayagam J, Zuma AA, Silva STDM, 
Jaisankar P, et al. Isobenzofuranone 
derivative JVPH3, an inhibitor of L. 
donovani topoisomerase II, disrupts 
mitochondrial architecture in 
trypanosomatid parasites. Scientific 
Reports. 2018;8:11940. DOI: 10.1038/
s41598-018-30405-w
[152] Chowdhury SR, Kumar A, 
Godinho JLP, De Macedo Silva ST, 
Zuma AA, Saha S, et al. Voacamine 
alters Leishmania ultrastructure 
and kills parasite by poisoning 
unusual bi-subunit topoisomerase 
IB. Biochemical Pharmacology. 
2017;138:19-30. DOI: 10.1016/j.
bcp.2017.05.002
[153] Brunoro GV-F, Caminha MA, 
Menna-Barreto RF. From proteins 
to molecular targets: Trypanosoma 
cruzi proteomic insights in drug 
development. In: Protozoan Parasitism: 
From Omics to Prevention and Control. 
Caister Academic Press; 2018;1:1-30. 
DOI: 10.21775/9781910190838.01
[154] Magalhães AD, Charneau S,  
Paba J, Guércio RAP, Teixeira ARL, 
Santana JM, et al. Trypanosoma cruzi 
alkaline 2-DE: Optimization and 
application to comparative proteome 
analysis of flagellate life stages. 
Proteome Science. 2008;6:24. DOI: 
10.1186/1477-5956-6-24
[155] Queiroz RML, Charneau S, Bastos 
IMD, Santana JM, Sousa MV, Roepstorff 
P, et al. Cell surface proteome analysis 
of human-hosted Trypanosoma cruzi life 
stages. Journal of Proteome Research. 
2014;13:3530-3541. DOI: 10.1021/
pr401120y
[156] de Jesus LTC, Calderano SG, 
Vitorino FN d L, Llanos RP, Lopes M 
d C, de Araújo CB, et al. Quantitative 
proteomic analysis of replicative and 
nonreplicative forms reveals important 
insights into chromatin biology of 
Trypanosoma cruzi. Molecular & 
Cellular Proteomics. 2017;16:23-38. DOI: 
10.1074/mcp.M116.061200
[157] Alves MJM, Kawahara R, Viner R, 
Colli W, Mattos EC, Thaysen-Andersen 
27
Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease
DOI: http://dx.doi.org/10.5772/intechopen.84472
M, et al. Comprehensive glycoprofiling 
of the epimastigote and trypomastigote 
stages of Trypanosoma cruzi. Journal 
of Proteomics. 2017;151:182-192. DOI: 
10.1016/j.jprot.2016.05.034
[158] Atwood JA, Minning T, Ludolf 
F, Nuccio A, Weatherly DB, Alvarez-
Manilla G, et al. Glycoproteomics of 
Trypanosoma cruzi trypomastigotes using 
subcellular fractionation, lectin affinity, 
and stable isotope labeling. Journal of 
Proteome Research. 2006;5:3376-3384. 
DOI: 10.1021/pr060364b
[159] de Godoy LMF, Marchini FK, 
Pavoni DP, Rampazzo R de CP, Probst 
CM, Goldenberg S, et al. Quantitative 
proteomics of Trypanosoma cruzi 
during metacyclogenesis. Proteomics. 
2012;12:2694-2703. DOI: 10.1002/
pmic.201200078
[160] Cordero EM, Nakayasu ES, Gentil 
LG, Yoshida N, Almeida IC, da Silveira 
JF. Proteomic analysis of detergent-
solubilized membrane proteins 
from insect-developmental forms of 
Trypanosoma cruzi. Journal of Proteome 
Research. 2009;8:3642-3652. DOI: 
10.1021/pr800887u
[161] Bayer-Santos E, Aguilar-Bonavides 
C, Rodrigues SP, Cordero EM, Marques 
AF, Varela-Ramirez A, et al. Proteomic 
analysis of Trypanosoma cruzi 
secretome: Characterization of two 
populations of extracellular vesicles and 
soluble proteins. Journal of Proteome 
Research. 2013;12:883-897. DOI: 
10.1021/pr300947g
[162] de Pablos Torró LM, Retana 
Moreira L, Osuna A. Extracellular 
vesicles in Chagas disease: A new 
passenger for an old disease. Frontiers 
in Microbiology. 2018;9:E1190. DOI: 
10.3389/fmicb.2018.01190
[163] Brunoro GVF, Caminha MA, 
Ferreira AT d S, Leprevost F d 
V, Carvalho PC, Perales J, et al. 
Reevaluating the Trypanosoma cruzi 
proteomic map: The shotgun description 
of bloodstream trypomastigotes. Journal 
of Proteomics. 2015;115:58-65. DOI: 
10.1016/j.jprot.2014.12.003
[164] Brunoro GVF, Faça VM, Caminha 
MA, Ferreira AT d S, Trugilho M, de 
Moura KCG, et al. Differential gel 
electrophoresis (DIGE) evaluation of 
naphthoimidazoles mode of action: A 
study in Trypanosoma cruzi bloodstream 
trypomastigotes. PLoS Neglected 
Tropical Diseases. 2016;10:e0004951. 
DOI: 10.1371/journal.pntd.0004951
[165] Paba J, Santana JM, Teixeira 
ARL, Fontes W, Sousa MV, Ricart 
CAO. Proteomic analysis of the 
human pathogen Trypanosoma cruzi. 
Proteomics. 2004;4:1052-1059. DOI: 
10.1002/pmic.200300637
[166] Ritagliati C, Alonso VL, Manarin 
R, Cribb P, Serra EC. Overexpression 
of cytoplasmic TcSIR2RP1 and 
mitochondrial TcSIR2RP3 impacts on 
Trypanosoma cruzi growth and cell 
invasion. PLoS Neglected Tropical 
Diseases. 2015;9:e0003725. DOI: 
10.1371/journal.pntd.0003725
[167] Moretti NS, da Silva Augusto L, 
Clemente TM, Antunes RPP, Yoshida N, 
Torrecilhas AC, et al. Characterization 
of Trypanosoma cruzi Sirtuins as 
possible drug targets for Chagas 
disease. Antimicrobial Agents and 
Chemotherapy. 2015;59:4669-4679. 
DOI: 10.1128/AAC.04694-14
[168] Gaspar L, Coron RP, KongThoo 
Lin P, Costa DM, Perez-Cabezas 
B, Tavares J, et al. Inhibitors of 
Trypanosoma cruzi Sir2 related protein 
1 as potential drugs against Chagas 
disease. PLoS Neglected Tropical 
Diseases. 2018;12:e0006180. DOI: 
10.1371/journal.pntd.0006180
[169] Wan X, Wen J-J, Koo S-J, Liang 
LY, Garg NJ. SIRT1-PGC1α-NFκB 
pathway of oxidative and inflammatory 
stress during Trypanosoma cruzi 
infection: Benefits of SIRT1-targeted 
therapy in improving heart function 
Biology of Trypanosoma cruzi
28
in Chagas disease. PLoS Pathogens. 
2016;12:e1005954. DOI: 10.1371/journal.
ppat.1005954
[170] Urbina JA. Specific chemotherapy 
of Chagas disease: Relevance, current 
limitations and new approaches. Acta 
Tropica. 2010;115:55-68. DOI: 10.1016/j.
actatropica.2009.10.023
[171] Filardi LS, Brener Z. Susceptibility 
and natural resistance of Trypanosoma 
cruzi strains to drugs used clinically 
in Chagas disease. Transactions of the 
Royal Society of Tropical Medicine 
and Hygiene. 1987;81:755-759. DOI: 
10.1016/0035-9203(87)90020-4
[172] Chatelain E, Ioset J-R. Phenotypic 
screening approaches for Chagas  
disease drug discovery. Expert  
Opinion on Drug Discovery. 
2018;13:141-153. DOI: 
10.1080/17460441.2018.1417380
[173] Moraes CB, Franco CH. Novel 
drug discovery for Chagas 
disease. Expert Opinion on Drug 
Discovery. 2016;11:447-455. DOI: 
10.1517/17460441.2016.1160883
[174] Sueth-Santiago V, Decote-Ricardo 
D, Morrot A, Freire-de-Lima CG,  
Lima MEF. Challenges in the 
chemotherapy of Chagas disease: 
Looking for possibilities related to  
the differences and similarities between 
the parasite and host. World Journal of 
Biological Chemistry. 2017;8:57. DOI: 
10.4331/wjbc.v8.i1.57
[175] Moraes CB, Giardini MA, Kim 
H, Franco CH, Araujo-Junior AM, 
Schenkman S, et al. Nitroheterocyclic 
compounds are more efficacious than 
CYP51 inhibitors against Trypanosoma 
cruzi: Implications for Chagas disease 
drug discovery and development. 
Scientific Reports. 2014;4:4703. DOI: 
10.1038/srep04703
[176] Cal M, Ioset J-R, Fügi MA, Mäser P, 
Kaiser M. Assessing anti-T. cruzi 
candidates in vitro for sterile cidality. 
International Journal for Parasitology: 
Drugs and Drug Resistance. 2016;6:165-
170. DOI: 10.1016/j.ijpddr.2016.08.003
[177] Ferraz ML, Gazzinelli RT, Alves 
RO, Urbina JA, Romanha AJ. Absence 
of CD4+ T lymphocytes, CD8+ T 
lymphocytes, or B lymphocytes has 
different effects on the efficacy of 
posaconazole and benznidazole in 
treatment of experimental acute 
Trypanosoma cruzi infection. 
Antimicrobial Agents and 
Chemotherapy. 2009;53:174-179. DOI: 
10.1128/AAC.00779-08
[178] Chatelain E, Ioset J-R. Drug 
discovery and development for 
neglected diseases: The DNDi model. 
Drug Design, Development and 
Therapy. 2011;5:175-181. DOI: 10.2147/
DDDT.S16381
[179] Friggeri L, Hargrove TY, 
Rachakonda G, Blobaum AL, Fisher 
P, de Oliveira GM, et al. Sterol 
14α-demethylase structure-based 
optimization of drug candidates for 
human infections with the protozoan 
trypanosomatidae. Journal of Medicinal 
Chemistry. 2018;61:10910-10921. DOI: 
10.1021/acs.jmedchem.8b01671
[180] Machado-Silva A, Cerqueira 
PG, Grazielle-Silva V, Gadelha FR, 
Peloso E de F, Teixeira SMR, et al. 
How Trypanosoma cruzi deals with 
oxidative stress: Antioxidant defence 
and DNA repair pathways. Mutation 
Research. Reviews in Mutation 
Research. 2016;767:8-22. DOI: 10.1016/j.
mrrev.2015.12.003
[181] Tomás AM, Castro H. Redox 
metabolism in mitochondria of 
trypanosomatids. Antioxidants & 
Redox Signaling. 2013;19:696-707. DOI: 
10.1089/ars.2012.4948
[182] Sykes ML, Avery VM. Approaches 
to protozoan drug discovery: 
Phenotypic screening. Journal of 
29
Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease
DOI: http://dx.doi.org/10.5772/intechopen.84472
Medicinal Chemistry. 2013;56:7727-
7740. DOI: 10.1021/jm4004279
[183] Peña I, Pilar Manzano M, Cantizani 
J, Kessler A, Alonso-Padilla J, Bardera AI, 
et al. New compound sets identified from 
high throughput phenotypic screening 
against three kinetoplastid parasites: 
An open resource. Scientific Reports. 
2015;5:8771. DOI: 10.1038/srep08771
[184] Chatelain E, Konar N. Translational 
challenges of animal models in Chagas 
disease drug development: A review. 
Drug Design, Development and Therapy. 
2015;9:4807-4823. DOI: 10.2147/DDDT.
S90208
